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The Second FEBS Advanced Lecture Course on Human Fungal Pathogens: Molecular Mechanisms
of Host-Pathogen Interactions and Virulence, organized by Christophe d’Enfert (Institut Pasteur,
France), Anita Sil (UCSF, USA), and Steffen Rupp (Fraunhofer, IGB, Germany), occurred May 2007
in La Colle sur Loup, France. Here we review the advances presented and the current state of knowl-
edge in key areas of fungal pathogenesis.The Second FEBS Advanced Lecture Course on Human
Fungal Pathogens: Molecular Mechanisms of Host-
Pathogen Interactions and Virulence brought together in-
vestigators and students from across the globe to a beau-
tiful sunny setting in Provence, France. This course, which
was attended by 40 investigators, both European and
non-European, and approximately 130 students provided
a state-of-the-art introduction to key concepts of human
fungal pathogenesis.
Fungi are important infectious agents of both immuno-
competent and immunocompromised individuals. There-
fore, as the population of immunosuppressed individuals
has increased secondary to HIV infection, cancer/che-
motherapy, organ transplantation, or autoimmune dis-
order, the incidence of fungal disease has surged. For in-
stance, the yeasts Candida are the fourth most common
pathogens isolated from nosocomial bloodstream infec-
tions (Edmond et al., 1999). The human pathogenic fungi
are broadly classified into two groups: the commensals,
such as Candida spp., dermatophytes, and Malassezia
spp., which are normal constituents of the human micro-
flora and generally cause disease in the setting of altered
host defenses, and the environmental pathogens, such
as Cryptococcus neoformans, and the thermally dimor-
phic fungi (Histoplasma capsulatum, Blastomyces derma-
titidis, Paracoccidioides brasiliensis, Coccidioides immi-
tis, Penicillium marneffei, and Sporothrix schenckii)
(Figure 1), which reside in specific environmental niches,
and humans are exposed by inhaling spores or small
yeast cells. The spectrum of fungal disease varies widely
from cutaneous skin or nail infections to life-threatening
disseminated disease. Despite an increasing incidence
of fungal infections and significant morbidity and mortal-
ity, treatment strategies are often ineffective due to de-
lays in treatment caused by suboptimal diagnostics, un-
desirable side effects and drug-drug interactions, and
increasing incidence of antifungal resistance among
pathogens. Although this meeting covered an array of
human fungal pathogens, several themes and key topics
emerged, including how virulence has evolved in patho-
genic fungi, the role of dimorphism in virulence, thedynamic interplay between host and pathogen, new
antifungal strategies, and the power of genomics and
studies of sexual reproduction in human pathogenic
fungi. This report offers an opportunity to review the
state of the field and discuss these areas of fungal path-
ogenesis.
Evolution of Virulence in Microbial Pathogens
Of threats to human health, none are as pervasive and
myriad as infectious diseases. Howmicrobes evolve to in-
teract with human hosts, in commensal and disease
states, is a key question in all fields of microbial pathogen-
esis. Arturo Casadevall (Albert Einstein, USA) advanced
two hypotheses for the evolution of fungal pathogens in
an opening plenary lecture. The first hypothesis posits
that some fungal pathogens have specifically evolved to
interact with the human host. In support of this theory
are clear examples in which virulence attributes may
have evolved in response to human-human, animal-
human, or animal-environment-animal/human cycles. For
this group of organisms that includes Candida spp.,
virulence reflects a disruption of the host-microbe rela-
tionship. The second hypothesis suggests that human en-
counters with fungal pathogens are entirely accidental,
and that these are not coevolved human pathogens.
Rather, the capacity for mammalian virulence for these
fungi evolved in heterologous environmental hosts, in-
cluding amoeba, slime molds, insects, and plants, which
selected for broad host range virulence determinants
that inadvertently enabled survival in human hosts (Steen-
bergen and Casadevall, 2006).
Evidence for the specific evolution of fungal pathogens
to human hosts derives from studies of Pneumocystic jir-
ovecii (Melanie Cushion, University of Cincinnati, USA;
Moira Cockell, CHUV, Switzerland) and the Microspori-
dia. Infection with Pneumocystis occurs via the respira-
tory tract, presumably via human-human transmission
like Mycobacterium tuberculosis. Pneumocystis occurs
as several closely related host-specific species, and
these are only known to proliferate in lungs of infected
mammals. The absence of any known environmentalCell Host & Microbe 2, August 2007 ª2007 Elsevier Inc. 77
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For each fungus, the source and disease spectrum are described along with an accompanying image.
(1) C. albicans yeast and hyphal cells. Adapted by permission fromMacmillan Publishers Ltd: Nature Reviews Genetics (Berman and Sudbery, 2002).
(2) Light microscopy of Diff-Quick-stained Pneumocystis wakefieldiae depicting five cysts. The top left cyst is a mature ascus containing all eight as-
cospores. The two cysts on the right represent immature forms containing naked nuclei. The remaining cysts are mature forms in various stages of
excystment. Picture courtesy of Melanie Cushion (University of Cincinnati, USA).
(3) Phase contrast microscopy of Histoplasma capsulatum mycelial (environmental) form depicting hyphae and conidia. Courtesy of http://www.
doctorfungus.org/ (ª2007).
(4) Yeast form cells of Blastomyces dermatitidis. Reproduced from The Journal of Experimental Medicine, 1999, Volume 189, issue number 8; issue
cover image (ª1999; The Rockefeller University Press).
(5) Periodic Acid Schiff (PAS) staining ofMalassezia in a skin biopsy specimen from a patient with seborrhoeic dermatitis. Courtesy of Annika Schey-
nius (Karolinska Institutet, Stockholm, Sweden).
(6) India ink preparation of C. neoformans highlighting the polysaccharide capsule surrounding the yeast cells. Courtesy of Alexander Idnurm (Duke
University, USA).reservoir suggests that human-human transmission
provides selective pressure to maintain virulence attri-
butes for mammalian infection. Similarly, Microsporidia
require the safe harbor of an infected mammal. In con-
trast to Pneumocystis, Microsporidia have dramatically
reduced genomes (3.5 MB) and likely derive key fac-
tors for survival from the host (Keeling and Slamovits,
2004). Transmission occurs from human to human, pro-
viding selective pressure for the maintenance of viru-
lence.
The dermatophytes (such as Trichophyton spp.) and
skin-associated commensals (such as the yeastMalasse-
zia) are perhaps the most successful human fungal patho-
gens. As the causes of athlete’s foot and skin, scalp, and
nail infections, dermatophytes are ubiquitous and afflict
the majority of the population. These fungi spread via
both direct human-human contact and infected fomites
and are specialized to utilize nutrients available from the
human body, including keratin and lipids in sebaceous se-
cretions. They evade immune detection by residing in
poorly vascularized tissues of lower temperature or in
which immunity is less effective. These fungal pathogens78 Cell Host & Microbe 2, August 2007 ª2007 Elsevier Inc.therefore likely evolved to specifically colonize mamma-
lian hosts.
Human-to-human transmission has been documented
for Candida spp., particularly Candida parapsilosis (Geral-
dine Butler, University College Dublin, Ireland), a common
commensal of the skin that can be transferred directly
from person to person, best characterized in the setting
of health care workers to patients. Transmission also oc-
curs via oral-oral or fecal-oral transmission and can lead
to disease in a variety of settings, including systemic dis-
ease in neutropenic hosts, oropharyngeal infection
(thrush) in the setting of AIDS, and vaginitis in otherwise
healthy women. Thus, in four quite divergent genera,Can-
dida, Pneumocystis, Microsporidia, and the dermato-
phytes/skin commensals, human fungal pathogens have
evolved in concert with mammalian hosts, suggesting
that for these pathogens virulence is not an accidental
encounter, but an evolved trait.
In contrast to the human commensal fungi, there is
a panoply of environmental pathogenic fungi. In these
cases, virulence may result from accidental host encoun-
ters, or from virulence evolution in heterologous hosts.
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(Aspergillus fumigatus), pathogenic yeasts (Cryptococcus
neoformans, Cryptococcus gattii), and the dimorphic fun-
gal pathogens (Histoplasma capsulatum, Blastomyces
dermatitidis, Paracoccidioides brasiliensis, Coccidioides
immitis,Penicilliummarneffei,Sporothrix schenckii). These
environmental pathogenic microbes share unifying fea-
tures, including occurrence in specific environmental
niches (soil, trees, bats, guano), and the fact that humans
are exposed by inhaling spores or small desiccated yeast
cells, leading to an initial pulmonary infection.
Initial encounters between these fungi and humans may
have been accidental, but their sophisticated interactions
with the host, from sensing carbon dioxide to facultative
intracellular survival in phagocytic immune cells, suggests
that their successful virulence strategies are under selec-
tive pressure. Whether this results from convergent evolu-
tion to survival in heterologous hosts and mammals
(the dual-use virulence factor hypothesis [Casadevall
et al., 2003]) or selection via animal-animal or animal-
environment-animal transmission remains to be explored.
These examples highlight how little is known about the
natural ecology of these organisms and how virulence
evolved and is maintained.
Genomics
Advancements in deciphering the molecular processes
that lead to virulence during fungal infections have been
hampered by difficulties in manipulating the diverse fungal
species that colonize and infect human hosts. Develop-
ment of DNA transformation systems for fungal organisms
single-handedly catapulted the field of fungal pathogene-
sis into the molecular era. More than 20 pathogenic fungal
species can be manipulated by direct DNA transformation
or Agrobacterium tumefaciens transconjugation. Avail-
ability of the complete genome sequence for major agents
of human mycoses (C. albicans, C. neoformans, Aspergil-
lus fumigatus, Coccidioides immitis, H. capsulatum) pro-
pelled the field into the genomics and postgenomics era,
providing new tools for genome-wide and comparative
genomic analysis. Genomics has also had great impact
among fungal pathogens that are recalcitrant to DNA
transformation and thus have been excluded from the
advances of the molecular era.
The power of genomics for intractable species was ex-
emplified by studies from Melanie Cushion’s group (Uni-
versity of Cincinnati, USA) on Pneumocystis carinii (Cush-
ion et al., 2007). Pneumocystis spp. are pathogens that
reside in alveoli of mammalian hosts and are the most
common etiological agents of acute fungal pneumonia in
immunocompromised individuals. Causative factors as-
sociated with Pneumocystis mycoses are challenging to
decipher because Pneumocystis species cannot be cul-
tured. Analysis of an EST library constructed fromP. carinii
organisms harvested from rats with fulminant pneumonia
revealed a high abundance of Major Surface Glycoprotein
(MSG) transcripts. These Pneumocystis-specific genes
comprise a glycoprotein family thought to facilitate es-
cape from immune detection. They also have adhesionproperties enabling cell-cell interactions and host cellular
adhesion. Additional analysis revealed an abundance of
transcripts involved in metabolic functions, suggesting
that P. cariniimay be capable of survival without scaveng-
ing host resources. Interestingly, several genes related to
the sexual cycle were identified, suggesting that sex may
occur in the mammalian lung during infection. The ability
of P. carinii to sustain metabolism and undergo sexual re-
production inside the host resembles plant biotrophic
fungi. These fungi complete their entire life cycle in plants
and are incapable of ex vivo growth. This resemblance led
Cushion to postulate that, like biotrophs that are ‘‘compat-
ible’’ with their hosts, a similar interrelationship can be ap-
plied to Pneumocystis. Without the need to damage the
host during nutrient acquisition, Pneumocystis has
evolved a sustainable or ‘‘compatible’’ relationship with
the host. However, under conditions that lead to immuno-
suppression, this relationship is altered, resulting in
disease.
In addition to serving as a platform to study intractable
fungi, genomics provides insights into more experimen-
tally amenable fungi. The virtues of genomics were illus-
trated by Malcolm Whiteway (McGill University, Canada)
in studies of the regulatory circuitry controlling galactose
utilization in C. albicans (Martchenko et al., 2007). In the
related fungus Saccharomyces cerevisiae, the transcrip-
tional regulation of galactose-metabolizing genes is con-
trolled by an upstream activating sequence, UASGal4,
that recruits the transcriptional activator Gal4. By compar-
ative genomics, Whiteway’s group found that, although
the C. albicans galactose utilization gene homologs are
syntenic, the upstream regulatory sequences have di-
verged, and the C. albicans UASGal4 sequence directs
the transcription of a different gene set. Furthermore, tran-
scriptional induction of galactose-metabolizing genes re-
quires the transcription factor Cph1 and is independent
of CaGal4. Thus, although S. cerevisiae and C. albicans
have maintained similar machinery for galactose metabo-
lism, the regulatory circuitry has diverged, resulting in
a transcriptional ‘‘rewiring,’’ possibly as C. albicans adap-
ted to the human host. Comparative genomics, not only of
promoter sequences, but also of whole genomes, prom-
ises to be a robust tool for global comparisons of gene
families and signaling pathways to identify both conserved
and novel biological processes in closely related species.
Sex and Evolution
How pathogenic fungi undergo sexual reproduction has
undergone a renaissance as genome sciences allowed
the identification of mating-type loci (MAT or MTL) and
machinery for mating and meiosis. C. albicans was
thought to be strictly asexual for more than a century,
and yet with the identification of the MTL and conditions
that support mating, it is clear that this organism is more
sexual than anticipated. Geraldine Butler (University Col-
lege Dublin, Ireland) and J.L.R. (Duke University, USA) ex-
amined genomes of other Candida species with complete
sexual cycles including meiosis, C. lusitaniae and C. guil-
liermondii, emerging causes of infections in humans. TheCell Host & Microbe 2, August 2007 ª2007 Elsevier Inc. 79
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tent throughout theCandida species, including three novel
genes encoding a predicted poly A polymerase, an oxy-
sterol-binding protein, and phosphatidylinositol-4 kinase.
All of the machinery for sexual reproduction is maintained,
but key elements predicted to be essential for meiosis are
missing from all Candida spp., including the two species
with complete meiotic sexual cycles, and also in C. albi-
cans, which is thought not to undergo meiosis. Thus, ei-
ther these components are dispensable or these species
undergo a parasexual reduction of their genomes, with
potential low levels of recombination.
Sexual reproduction is thought to be a crucial part of the
infectious life cycle for some fungal pathogens, particu-
larly for the environmental fungi such as C. neoformans.
This organism is found in association with pigeon guano,
soil, and trees, and humans are exposed by inhaling small
particles either as desiccated yeast cells or spores pro-
duced via mating in the environment. A novel gradient
centrifugation approach to purify spores was developed
(Christina Hull/Steven Giles, University of Wisconsin-
Madison, USA), allowing detailed genetic, morphological,
and virulence studies of spores. These studies revealed
that spores can be more infectious than yeasts in some
virulence studies. Spores are readily phagocytosed by
macrophage cell lines, even without added opsonins, in
contrast to yeast cells. Similarly, studies were presented
that conidia (asexual spores) from the dimorphic pathogen
H. capsulatum (Anita Sil/Charlotte Berkes, UCSF, USA)
are phagocytosed by macrophages, and an interferon re-
sponse more typical of viral infection is induced in host
immune cells. Novel therapeutic approaches involving
interferons already in clinical use for viral infections could
be a possibility.
For the environmental fungi, sex may play an important
part in the life cycle to generate the infectious particles
that are inhaled by humans. However, for some commen-
sal fungal species, such as Candida, there appears to be
a negative correlation between the ability to complete
a full meiotic sexual cycle (including spore formation)
and success as a pathogen. For instance, C. albicans,
C. parapsilosis, and C. glabrata are the most prominent
Candida spp. causing infection, but all three lack complete
sexual cycles. In contrast,C. lusitaniae andC. guilliermon-
dii possess complete sexual cycles but are less frequent
causes of candidiasis. Interestingly, the dermatophytic
fungi also show a similar trend, suggesting that meiosis
may actually be disadvantageous to certain pathogens.
Whether the absence of a complete meiotic sexual cycle
with spore formation is a trait that occurred as a prelude
to human-human transmission and virulence is an open
question.
Environmental Sensing and Morphogenesis
A common trait shared by environmental pathogenic fungi
is the induction of a morphogenic transition upon infection
of the mammalian host. Whether this transition is an
evolved trait or not remains to be determined. However,80 Cell Host & Microbe 2, August 2007 ª2007 Elsevier Inc.this poses another fundamental question central to fungal
pathogenesis: does morphogenesis promote virulence?
Avarietyof human fungalpathogenscangrow inmultiple
morphological forms (commonly as yeast or hyphae). The
human primary fungal pathogens (Blastomyces dermatiti-
dis, Histoplasma capsulatum, Paraccocidioides brasilien-
sis, and Coccidioides immitis) exist as mycelia (the hyphal
form) in the environment; however, inhalation of conidia
(asexual spores) by the host results in a temperature-
induced mycelium-to-yeast transition. Hence, these spe-
cies are referred to as thermally dimorphic fungi. This mor-
phological transition is a critical prelude to infection, as
Bruce Klein (University of Wisconsin, USA) demonstrated
throughwork on a key regulator of the dimorphic transition
in Blastomyces dermatitidis. Using an Agrobacterium tu-
mefaciens T-DNA insertional mutagenesis approach, his
laboratory identified a histidine kinase gene (Drk1), homol-
ogous to Saccharomyces cerevisiae Sln1, which when ab-
lated locked B. dermatitidis in the mold phase. Virulence
studies demonstrate that strains lacking Drk1 are attenu-
ated, and DRK1 silencing in Histoplasma capsulatum
also reduced virulence (Nemecek et al., 2006), providing
evidence linking morphogenesis to virulence.
The commensal fungus Candida albicans is also dimor-
phic. In contrast to the thermally dimorphic fungi, both
yeast and hyphae of C. albicans are found in the infected
human host. While the hyphal phase is associated with tis-
sue adhesion and invasion, the yeast phase is thought to
be important for dissemination during systemic infection.
As discussed by Alistair Brown (University of Aberdeen,
UK), key genes that regulate dimorphic transitions in
C. albicans have been identified, and genetic ablation re-
sults in strains locked in the yeast (cph1/cph1 efg1/efg1
strains) or (pseudo)hyphal phase (nrg1/nrg1 and tup1/tup1
strains). Virulence studies in a murine systemic infection
model revealed that both types are avirulent (Lo et al.,
1997; Murad et al., 2001; Saville et al., 2003), suggesting
both budding and filamentous morphotypes are important
for pathogenesis. However, caution is warranted with this
interpretation, since EFG1, CPH1, NRG1, and TUP1 regu-
late other virulence factors not linked to morphogenesis.
The hyphae-specific cyclin gene HGC1 was recently
shown to be required for hyphal development in C. albi-
cans (Zheng et al., 2004). Under all conditions tested,
hgc1/hgc1 mutants failed to form hyphae and exhibited
attenuated virulence. Further analysis showed that Hgc1
interacts with the Cdc28 kinase, suggesting that Hgc1
promotes hyphal development by regulating apical elon-
gation. As with B. dermatitidis, these findings provide fur-
ther evidence that morphological transitions are required
for pathogenicity of dimorphic fungi.
The interplay between host signals and dimorphic tran-
sitions has been elegantly demonstrated in C. albicans.
During adaptation to different host niches, C. albicans
has evolved sophisticated mechanisms for sensing and
responding to various environmental factors (Biswas
et al., 2007). One mechanism is its ability to respond to
low oxygen levels (hypoxia) in the anaerobic environment
of the gastrointestinal tract. As presented by Siobhan
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adaptation to hypoxic conditions relies on the yeast fila-
mentous transition. This transition is dependent on the
transcription factor Ace2, which regulates genes involved
in cellular respiration and filamentous growth under hyp-
oxic conditions (Mulhern et al., 2006). Induction of C. albi-
cans filamentation during hypoxic conditions provides an-
other example of the importance of morphogenesis during
host colonization. In conclusion, mounting evidence ar-
gues strongly for a role of dimorphism during fungal path-
ogenesis (Rooney and Klein, 2002), providing a promising
therapeutic avenue for treatment of human mycoses.
Host-Pathogen Interactions
Understanding the molecules mediating interactions at
the host-fungal interface is crucial to developing new ap-
proaches for treatment and management of fungal infec-
tions. From the pathogen’s perspective, this includes
identification of key virulence factors that allow the patho-
gen to cause disease (such as morphogenesis) or to es-
cape immune detection by subverting innate immunity.
Numerous species-specific virulence factors have been
described, such as the ability of Cryptococcus to elabo-
rate a polysaccharide capsule and produce melanin (Guil-
hem Janbon, Institut Pasteur, France; Arturo Casadevall,
Albert Einstein, USA) (Casadevall and Perfect, 1998).
Other virulence factors, such as the ability to grow at hu-
man body temperature and adherence to host tissues,
are universal among fungal pathogens, although the spe-
cific molecules and pathways involved often differ. Con-
versely, from the host perspective, this involves elucidat-
ing the mechanisms by which the host recognizes and
responds to fungal pathogens, resulting in containment
of infection, or in some cases, an overzealous immune
response, leading to allergy and inflammation.
The damage response network hypothesis was pre-
sented by Arturo Casadevall (Albert Einstein, USA) as
a model to conceptualize host-fungal interactions (Casa-
devall and Pirofski, 2003). According to this hypothesis,
there are two primary host immunological states under
which disease occurs. The first disease state results
from a weak immune response. This is the case for
many fungal pathogens, such as Cryptococcus and
Aspergillus, which cause disease primarily in patients
with immunodeficiencies secondary to transplantation,
cancer, or HIV infection. However, a weak immune re-
sponse can also result from the fungal pathogen’s ability
to camouflage or shield itself from immune recognition
(Neil Gow, University of Aberdeen, UK). The second dis-
ease state occurs in the presence of an overzealous im-
mune response to a fungal pathogen, such as occurs in
patients with recurrent vulvovaginal candidiasis (Fidel,
2007), immune reconstitution syndrome with Cryptococ-
cus (Singh et al., 2005), allergic reaction to Aspergillus,
or sensitization to Malassezia spp. in the setting of atopic
eczema (Schmid-Grendelmeier et al., 2006).
Numerous tools and models have been harnessed to
elucidate the host-fungus interaction and to learn how
the host recognizes and clears fungal pathogens (NeilGow, University of Aberdeen, UK). The utilization of model
host systems (Drosophila melanogaster, C. elegans, the
wax moth Galleria mellonella, mammalian models [mice,
rabbits, rats], human cell lines, and human reconstituted/
model tissues) to study fungal-host interactions (Casade-
vall, 2005; Schaller et al., 2006) has resulted in numerous
discoveries, including the identification of Toll-like recep-
tors involved in innate immune recognition of fungal path-
ogens (Lemaitre et al., 1996).
Insight into how the immune system recognizes fungal
pathogens has also revealed mechanisms by which these
pathogens evade host immunity. Work presented by Gor-
don Brown (University of Cape Town, South Africa) dem-
onstrated that the C-type lectin Dectin-1 is expressed by
multiple immune effector cells and recognizes b-glucans
(a fungal cell wall component) to mediate binding, uptake,
and killing of fungal pathogens (Brown, 2006). Interest-
ingly, coincident with the morphological transition from
mycelial to yeast growth upon infection of the human
host, thermally dimorphic fungi, such as H. capsulatum,
change their cell wall composition from primarily b-glucan
to predominately a-(1-3)-glucan. Elaboration of cell wall
a-(1,3)-glucan is positively correlated with pathogenicity,
but the reasonwas previously unknown.With new insights
into how the immune system recognizes fungal patho-
gens, William Goldman’s laboratory found that incorpora-
tion of a-(1,3)-glucan into the H. capsulatum cell wall con-
ceals b-glucans from detection by Dectin-1 (Rappleye
et al., 2007). Thus, understanding how the host senses
fungi provides insight into how pathogens subvert normal
immune responses resulting in a weak immune response.
Fungal disease can also result from an overzealous im-
mune response, as illustrated by Annika Scheynius’s anal-
ysis (Karolinska Institutet, Sweden) of the role thatMalas-
sezia species play in the immune disorder atopic eczema
(Schmid-Grendelmeier et al., 2006). Atopic eczema is
a chronic inflammatory skin disorder that develops when
defective skin barriers permit entry of environmental fac-
tors into cutaneous tissues, where they act as allergens
provoking an inappropriate inflammatory response.
Yeasts such asMalassezia are common skin commensals
in a majority of the population. Patients with atopic ec-
zema mount an exaggerated allergic immune response
toMalassezia that is not seen in patients with other allergic
diseases or normal hosts (Casagrande et al., 2006). Thus,
this normally commensal organism contributes to patho-
genesis by provoking allergic inflammation. Treatment
with the antifungal drug ketoconazole improves eczema,
suggesting that commensal fungi have an intimate role
in disease development. This clearly links a commensal
microbe to an overzealous, rather than deficient, immune
response resulting in disease. An understanding not only
of the pathogen, but also of how the host responds to
fungal pathogens, is crucial for the development of new
treatment strategies.
Antifungal and Vaccine Strategies
Of the microorganisms causing disease in humans, both
fungi and parasites are eukaryotic cells similar to ourCell Host & Microbe 2, August 2007 ª2007 Elsevier Inc. 81
Cell Host & Microbe
Meeting Reviewown cells, and thus finding suitable targets for antifungal
therapy is challenging. The current antifungal armamen-
tarium is limited, and treatment is complicated due to
side effects and drug-drug interactions. Current research
on antifungals focuses on three primary areas as de-
scribed by Dominique Sanglard (CHUV, Switzerland) in
an introductory talk: strategies to increase the efficacy of
existing antifungals, developing novel therapies, and un-
derstanding drug resistance.
Mortality from fungal infections increases with delayed
treatment; thus, empirical treatment is often initiated be-
fore culture-based identification. Improving current anti-
fungal therapeutics aims at developing diagnostic tools
such that causative agents can be identified earlier and
targeted treatment begun. Other research focuses on
novel drug combinations that could enhance efficacy of
available antifungals. One example is the azoles, normally
fungistatic drugs, which become fungicidal when com-
bined with calcineurin inhibitors (FK506 and Cyclosporine
A) (Steinbach et al., 2007). Although immunosuppressive
side effects of calcineurin inhibitors may limit systemic ap-
plication, some promise has been shown in treating fungal
eye and skin infections in model systems, settings in
which systemic side effects may be mitigated in patients
(Onyewu et al., 2006; Steinbach et al., 2007).
Other research focuses on developing novel antifungal
agents, including panfungal vaccines for patients at high
risk of fungal infections. The development of an antifungal
vaccine is a new concept, since previous dogma sug-
gested that to resolve fungal infections the host needed
to mount a Th-1 T cell-mediated immune response (Ro-
mani, 2004). The majority of individuals develop anti-
bodies to organisms such as C. albicans and C. neofor-
mans early in life; however, these polyclonal antibodies
do not always provide subsequent protection. One expla-
nation is that only some antibodies are beneficial, whereas
others could exacerbate disease (Cutler et al., 2007). Cur-
rent research focuses on developing monoclonal anti-
bodies to fungal epitopes that may enhance immune re-
sponse by mechanisms including neutralization of fungal
virulence factors or direct killing, opsonization, and stimu-
lation of cell-mediated immunity. Antonio Cassone (Insti-
tuto Superiore di Sanita, Italy) outlined the current state
of antifungal vaccine development. Various fungal pro-
teins (C. albicans Hsp90 and Als1, H. capsulatum Hsp60
and histone-H2B-like protein, and B. dermatitidis Bad1)
and carbohydrate antigens (C. neoformans capsule com-
ponent, GXM, andC. albicans short-chain b-1,2-linked oli-
gomannosides) have been utilized with variable results.
However, these antigens are relatively species specific,
and thus multiple vaccines would be required. b-1,3-
glucan, a primary component of the fungal cell wall, has
been proposed as a panfungal vaccine candidate; initial
studies suggest that protective antibody responses can
be generated (Rachini et al., 2007). Although fungal vac-
cines are advancing, there were questions raised during
discussions at the conference, including the efficacy of
these vaccines in immunodeficient hosts and potential
consequences of developing a vaccine to a commensal,82 Cell Host & Microbe 2, August 2007 ª2007 Elsevier Inc.such as C. albicans. This highlights our limited knowledge
concerning roles of Candida in the host in the nondisease
state.
The development of new antifungal strategies is needed
as resistance to current therapies emerges. Many mecha-
nisms of antifungal resistance have been characterized
(as discussed by Ted White, SBRI, USA), including upre-
gulation of efflux pumps and target genes, mutation of tar-
gets that reduce drug binding, or the elaboration of fungal
biofilms that are less susceptible to drugs. However, novel
mechanisms of antifungal drug resistance continue to be
discovered. For instance, Judith Berman (University of
Minnesota, USA) presented a novel mechanism of antifun-
gal resistance acquisition through the formation of an iso-
chromosome in response to fluconazole (Selmecki et al.,
2006). Using comparative genome hybridization, multiple
fluconazole-resistant isolates were identified with an in-
creased copy number of the left arm of chromosome 5,
which results from formation of an isochromosome pos-
sessing two chromosome 5L arms flanking a single cen-
tromere. There was a concomitant increase in expression
level of most genes on chromosome 5L, including two key
players in fluconazole resistance: ERG11 (encoding the
target of fluconazole, lanosterol-14a-demethylase) and
TAC1 (encoding a transcription factor that upregulates
expression of ABC transporters, Cdr1 and Cdr2, that
efflux fluconazole). The utilization of a genomics approach
to studying antifungal resistance highlights the dynamic
nature of the C. albicans genome and how genome plas-
ticity can confer antifungal resistance.
Conclusions and Outlook
The field of fungal pathogenesis has grown exponentially
over the past decades, particularly with the aid of com-
plete genome sequences that have allowed multiple ge-
nome comparisons and insight into genetically intractable
fungi. With more fungal genomes currently being assem-
bled (including Pneumocystis, dermatophyte, and Malas-
sezia species), the impact of genomics will continue to
grow. The expanding use of model host systems holds
promise for furthering our understanding of how the innate
immune system recognizes fungal pathogens, as well as
the virulence factors that fungi use to subvert the immune
response and cause disease in human hosts. However,
there are many questions that remain to be answered, in-
cluding understanding the nature of the infectious propa-
gule for fungi such as Cryptococcus and the dimorphic
fungal pathogens normally found in the environment.
With relatively few new antifungal drugs coming to market
(one new class within the past 25 years), and an increase
in organisms resistant to available therapies, there is an
urgent need to develop new therapeutics including drug
combinations, selective immune reconstitution, and vac-
cines. From studies presented at the meeting, the field is
advancing in elucidating virulence-associated mecha-
nisms, but less is appreciated about commensal relation-
ships on skin, the GI tract, and other mucosal surfaces. As
the NIH-supported human microbiome program ad-
vances, a focus should be examination of the fungal
Cell Host & Microbe
Meeting Reviewmicrobiome, and its relationship with bacterial microbiota
and host in both commensal and disease states.
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